Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer - Summary - MDSpire
From the Journals

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

“Elinzanetant is the first approved targeted agent for [the vasomotor symptoms] that deeply affect the quality of life of breast cancer patients. By helping patients to tolerate better their breast ca...

Share

Elinzanetant, a neurokinin-targeted therapy, provides significant relief from hot flashes and night sweats in patients undergoing hormone treatment for estrogen receptor-positive breast cancer, as demonstrated in the OASIS 4 clinical trial. Presented by Dr. Fatima Cardoso at the 15th European Breast Cancer Conference, findings indicate that elinzanetant offers consistent relief regardless of hormone therapy type. As a nonhormonal option, it reduces vasomotor symptoms without compromising cancer treatments, supporting better patient compliance and quality of life.

Original Source(s)

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

  • by The ASCO Post Staff

  • April 13, 2026

Related Content

PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%

A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biops...

Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors

Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring an...

FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers

WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas.

  • April 14, 2026

  • 2 min